Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Prophylaxis of Pneumocystis jiroveci pneumonia (PJP) with trimethoprim/sulfamethoxazole is a standard of care for children with hematologic malignancies, while its use in solid tumor patients is still debated. A retrospective study focusing on the use of PJP prophylaxis in patients with solid tumors was performed among 16 AIEOP centers: 1046/2863 patients did not receive prophylaxis and no cases of PJP were reported.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/INF.0000000000003044 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Systematic engineering of TROP2-targeted CAR T-cell therapy overcomes resistance pathways in solid tumors.
Cancer Immunol Res
September 2025
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.
Antibody-based therapies have revolutionized cancer treatment but have several limitations. These include: down-regulation of the target antigen; mutation of the target epitope; or in the case of antibody drug conjugates (ADCs), resistance to the chemotherapy warhead. Since TROP2-targeted therapy with ADCs yields responses in TROP2+ solid tumors but lacks the durability observed with other immunotherapy-based approaches, we developed novel TROP2-targeting chimeric antigen receptor (CAR) T cells as an alternative.
View Article and Find Full Text PDFPreclinical evaluation of folate receptor-alpha chimeric antigen receptor T cells (FOLR1-CART) exhibit highly efficient anti-tumor activity against osteosarcoma.
Cancer Res Commun
September 2025
Fred Hutchinson Cancer Center, Seattle, WA, United States.
Metastatic and relapsed osteosarcoma (OS) remains difficult to treat despite advanced surgical techniques, intensified chemotherapy, and targeted therapies. Adoptive immunotherapies such as chimeric antigen receptor (CAR) T cells, are in their nascent stage, but remain a viable therapeutic strategy for patients with aggressive solid tumors such as OS. Folate receptor- (FOLR1) has been functionally implicated in OS pathophysiology, providing rationale as a potential therapeutic target.
View Article and Find Full Text PDFEnhance therapeutic efficacy of BiTE (HER2/CD3) for HER2- positive tumors through expression.
Int J Pharm X
December 2025
Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, China, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China.
Bispecific T-cell engagers (BiTEs) are small-molecule antibodies that exhibits potent tumoricidal activity but suffer from a short plasma half-life. Mesenchymal stromal cells (MSCs) represent promising delivery vehicles for sustained therapeutic protein expression. In this study, we used human umbilical cord blood-MSCs (hUC-MSCs) as a delivery system to to secrete HER2/CD3 BiTE antibodies, thereby addressing the pharmacokinetic limitations of conventional BiTE therapies.
View Article and Find Full Text PDFRole and practical guidelines for the use of radiotherapy in neuroblastoma - a narrative review of literature and clinical trial protocols.
Rep Pract Oncol Radiother
August 2025
Department of Oncology, Wroclaw Medical University, Wroclaw, Poland.
Neuroblastoma is the most common extracranial solid tumor in children, requiring multidisciplinary treatment, including radiotherapy, which is primarily applied in the high-risk group to prevent disease progression. The review highlights indications for radiotherapy, its role in multimodal treatment, and addresses aspects of radiotherapy planning, including target volume definition, prescribed radiation doses, optimal timing for radiotherapy implementation, and potential side effects. Particular attention is drawn to the lack of consensus regarding the necessity of an additional radiation dose for persistent residual disease in the primary tumor and the irradiation of metastatic sites remaining after induction therapy.
View Article and Find Full Text PDFRetrospective analysis of clinical characteristics and treatment of patients with immune checkpoint inhibitors-induced adrenal insufficiency.
Front Oncol
August 2025
Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Background: Immune checkpoint inhibitors (ICIs) are effective against solid tumors but can trigger immune-related adverse events (irAEs), including adrenal insufficiency (AI). Given its impact on treatment efficacy and patient quality of life, understanding the clinical characteristics and outcomes of ICI-induced AI (ICI-AI) is critical.
Methods: We conducted a retrospective analysis of 46 patients diagnosed with ICI-AI at a single center (May 2019-July 2024) and reviewed clinical trials/real-world studies on ICI-AI.